Advertisement


Alicia Latham, MD, MS, on Using ctDNA to Detect Endometrial Cancer

2025 ASCO Annual Meeting

Advertisement

Alicia Latham, MD, MS, of Memorial Sloan Kettering Cancer Center, discusses the feasibility of using Pap-derived ctDNA for the detection of sporadic and Lynch syndrome–associated endometrial cancer (Abstract 10503). 



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
The study is important because for the longest time women's only option if they had an increased risk for gynecologic cancer because of hereditary predisposition like BRCA or Lynch syndrome or some of these other hereditary susceptibilities was they were recommended to and still are recommended to undergo risk-reducing hysterectomy. So it's a major quality of life issue. Right now, the only possible screening option for women with Lynch syndrome for uterine cancer is endometrial biopsy. The NCCN recommends that women can consider this. But unfortunately we know that they don't really work very well in terms of detecting uterine cancer as a pure screening test. And they're also very invasive and uncomfortable and cause a lot of pain. The idea behind the study is to try to develop a new way to screen for uterine cancer by using cell-free DNA, which we all know as more of a blood-based test, but in actuality, you can extract cell-free DNA from multiple body fluids. And so what the study has done is we looked at 16 patients with known uterine cancer that were going in for surgical operation, collected both a blood test and a cervical sample and extracted cell-free DNA from both body fluids. And then we compared tumor mutations, we sequenced them, compared tumor mutations in the actual tumor cancers to those that were found in the blood and those that were found in the cervical mucus sampling. And we found in what we're calling Pap ctDNA that over 90% of our mutations were detected in these early-stage cancers. In fact, it was 93% in FIGO grade 1 uterine cancer. In comparison, the blood test only detected about one-quarter of these. So we have a lot of work to do. This is a small feasibility study. We're in the process of expanding this more. I'm working on looking at other tumor types such as ovarian, which I've already been asked about, and hopefully we’ll be able to have an option for women for screening for these cancers for which they have not had effective screening.

Related Videos

Colorectal Cancer

Christopher M. Booth, MD, on a Structured Exercise Program for Patients With Colon Cancer

Christopher M. Booth, MD, of Queen’s University, reviews findings from the randomized phase III Canadian Cancer Trials Group (CCTG) CO.21 (CHALLENGE) trial, which evaluated the impact of a structured exercise program on disease-free survival in patients with stage III or high-risk stage II colon cancer (Abstract LBA3510). 

Colorectal Cancer

Heinz-Josef Lenz, MD, on MSI-H/dMMR Metastatic Colorectal Cancer: Expanded Analyses From CheckMate 8HW

Heinz-Josef Lenz, MD, of the University of Southern California Norris Comprehensive Cancer Center, reviews analyses from the CheckMate 8HW trial, which evaluated nivolumab plus ipilimumab vs chemotherapy or nivolumab monotherapy for microsatellite instability–high/mismatch repair–deficient (MSI-H/dMMR) metastatic colorectal cancer (Abstract 3501). 

Gastrointestinal Cancer

Yelena Y. Janjigian, MD, on Gastric/GEJ Cancer: Immunotherapy Plus FLOT

Yelena Y. Janjigian, MD, of Memorial Sloan Kettering Cancer Center, presents event-free survival data from the phase III MATTERHORN trial of the PD-L1 inhibitor durvalumab plus FLOT (fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy) in patients with resectable gastric or gastroesophageal junction (GEJ) cancer (LBA5). 

Lung Cancer

Luis G. Paz-Ares, MD, PhD, on Extensive-Stage SCLC: Comparison of First-Line Regimens

Luis G. Paz-Ares, MD, PhD, of Hospital Universitario 12 de Octubre, H12O-CNIO Lung Cancer Unit, Universidad Complutense and Ciberonc, discusses data from the TIGOS trial, a phase III study comparing the first-line use of atigotatug (an antifucosyl-GM1 monoclonal antibody) plus nivolumab fixed-dose combination with chemotherapy vs atezolizumab with chemotherapy in patients with  extensive-stage small cell lung cancer (SCLC) (Abstract TPS8127).

 

Ruben A. Mesa, MD, on Essential Thrombocythemia: SURPASS-ET Trial

Ruben A. Mesa, MD, of Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Wake Forest University School of Medicine, presents results from a phase III trial investigating the efficacy of ropeginterferon alfa-2b vs anagrelide for the treatment of essential thrombocythemia (Abstract 6500). 

 

Advertisement

Advertisement




Advertisement